Plasma corticotrophin response to desmopressin in patients with Cushing’s disease correlates with the expression of vasopressin receptor 2, but not with that of vasopressin receptor 1 or 3, in their pituitary tumours

Wang, Fan-Fen; Tang, Kuo‐Tung; Yen, Yu‐Shu; Ho, Donald Ming‐Tak; Yang, An-Hang; Huang, Chun‐Hsiang; Lin, Hong-Da; Won, Justin G.S.

doi:10.1111/j.1365-2265.2011.04179.x

Cited by 27 publications

(12 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AVP has been shown to induce a dose-dependent (from 1 nM) and time-persistent increase of tumor cell proliferation. V2 receptors are present in human breast cancer (47), cervical cancer (85), and lung cancer (95) cells and in corticotrophinomas, with V2Rs varying greatly, being lower in macroadenomas than in microadenomas (126). An abnormal truncated V2R was also detected in MCF-7 cells, although it appeared to be nonfunctional (87)(88)(89).…”

Section: Distribution and Function Of V2rsmentioning

confidence: 99%

See 1 more Smart Citation

The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors

Juul

Bichet

Nielsen

et al. 2014

American Journal of Physiology-Renal Physiology

125

View full text Add to dashboard Cite

Juul KV, Bichet DG, Nielsen S, Nørgaard JP. The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors. Am J Physiol Renal Physiol 306: F931-F940, 2014. First published March 5, 2014 doi:10.1152/ajprenal.00604.2013.-The arginine vasopressin (AVP) type 2 receptor (V2R) is unique among AVP receptor subtypes in signaling through cAMP. Its key function is in the kidneys, facilitating the urine concentrating mechanism through the AVP/V2 type receptor/aquaporin 2 system in the medullary and cortical collecting ducts. Recent clinical and research observations strongly support the existence of an extrarenal V2R. The clinical importance of the extrarenal V2R spans widely from stimulation of coagulation factor in the endothelium to as yet untested potential therapeutic targets. These include V2R-regulated membranous fluid turnover in the inner ear, V2R-regulated mitogensis and apoptosis in certain tumor tissues, and numerous other cell types where the physiological role of V2Rs still requires further research. Here, we review current evidence on the physiological and pathophysiological functions of renal and extrarenal V2Rs. These functions of V2R are important, not only in rare diseases with loss or gain of function of V2R but also in relation to the recent use of nonpeptide V2R antagonists to treat hyponatremia and possibly retard the growth of cysts and development of renal failure in autosomal dominant polycystic kidney disease. The main functions of V2R in principal cells of the collecting duct are water, salt, and urea transport by modifying the trafficking of aquaporin 2, epithelial Na ϩ channels, and urea transporters and vasodilation and stimulation of coagulation factor properties, mainly seen with pharmacological doses of 1-desamino-8-D-AVP. The AVPR2 gene is located on the X chromosome, in a region with high probability of escape from inactivation; this may lead to phenotypic sex differences, with females expressing higher levels of transcript than males. vasopressin V 2 receptor; arginine vasopressin V2 receptor; arginine vasopressin; desmopressin; extrarenal vasopressin V 2 receptor THE PURPOSE OF THIS REPORT is to review current evidence on the physiological and pathophysiogical functions of renal and extrarenal arginine vasopressin (AVP) type 2 receptors, referred to as V2Rs (Fig. 1).AVP is an important neurohypophyseal nonapeptide that, via its three receptor types, is primarily responsible for regulating osmotic homeostasis of body fluids, volume homeostasis, and vasoconstriction in addition to an array of central functions such as memory and learning (17,29). In addition to these endocrine functions, AVP also contributes to regulating mitogenesis, cell survival, and death (apoptosis) (77).AVP is released from its storage site in the posterior pituitary (Fig. 2) by highly sensitive osmotic stimuli, specifically by a Ͻ1-2% increase in plasma osmolarity, as originally detailed in the 1940s through classic research by Prof. E. B. Verney (125). AVP release may also ...

show abstract

Section: Distribution and Function Of V2rsmentioning

confidence: 99%

“…The presence of all AVP receptor subtypes, but particularly V2R, has been reported in transformed epithelial cells (86,89). V2R is present in a wide panel of human tumor cell lines, including human breast cancer cells (47), cervical cancer (85), lung cancer (95), and in corticotrophinomas (126).…”

mentioning

confidence: 99%

The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors

Juul

Bichet

Nielsen

et al. 2014

American Journal of Physiology-Renal Physiology

125

View full text Add to dashboard Cite

show abstract

“…After adjustment for tumor volume, a positive correlation was found between the percentage increment of ACTH and the degree of AVPR2 expression, but not between that of AVPR1 or AVPR1b. No relationship was observed between the level of CRHR expression in tumor tissues and the percentage increment or net AUC of ACTH to CRH administration in CD patients (123). Luque et al evaluated a total of eight normal pituitaries (NPs), 23 corticotropinomas, 14 non-functioning pituitary adenomas, 17 somatotropinomas and three prolactinomas for AVPR expression; corticotropinomas variably expressed all AVPR subtypesAVPR1b being the predominant subtype followed by AVPR2 OAVPR1a.…”

Section: Aberrant Receptors In CD and Other Endocrine Tumorsmentioning

confidence: 99%

Multiple aberrant hormone receptors in Cushing's syndrome

Ghorayeb

Bourdeau

Lacroix

2015

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Several studies have reported the expression of ectopic V 2 receptors in the adrenal glands (Lee et al, 2005;Louiset et al, 2008). Moreover, recent experimental studies have strongly supported the existence of an extrarenal V 2 receptor (Juul, Bichet, Nielsen, & Norgaard, 2014), including in transformed epithelial cells (North, 2000) and a number of human tumour cell lines (Iannucci et al, 2011;Noh et al, 2009;Wang et al, 2012). Considering the above, tolvaptan might have direct effects on adrenal aldosterone production via V 2 receptor antagonism.…”

mentioning

confidence: 92%

Novel molecular mechanisms in the inhibition of adrenal aldosterone synthesis: Action of tolvaptan via vasopressin V₂ receptor‐independent pathway

Ali

Dohi

Okamoto

et al. 2019

British J Pharmacology

View full text Add to dashboard Cite

Background and Purpose:We investigated the inhibitory effect and associated molecular mechanisms of tolvaptan on angiotensin II (AngII)-induced aldosterone production in vitro and in vivo.Experimental Approach: In vitro, H295R human adrenocarcinoma cells were incubated with 1 μmol·L −1 arginine vasopressin (AVP) or dDAVP, or tolvaptan (0.1, 1, and 3 μmol·L −1 ) in the presence and absence of 100 nmol·L −1 of AngII. In vivo, Sprague-Dawley rats were treated with tolvaptan 0.05% in the diet for 6 days in the presence and absence of 200 pmol·min −1 AngII.Key Results: Tolvaptan suppressed AngII-induced aldosterone production in a dose-dependent manner in H295R cells, whereas neither AVP nor dDAVP in the presence or absence of AngII altered aldosterone production, suggesting the vasopressin V 2 receptor was not involved in the inhibitory effect of tolvaptan on aldosterone synthesis. In addition, tolvaptan inhibited the AngII-induced increase in aldosterone synthase (CYP11B2) protein levels without suppressing CYP11B2 mRNA expression. Notably, tolvaptan increased the levels of unfolded protein response (UPR) marker DDIT3 and eIF2α phosphorylation (a UPR-induced event), which could block the translation of CYP11B2 mRNA into protein and thereby inhibit aldosterone production. In vivo, tolvaptan significantly inhibited AngII-induced increases in serum and adrenal aldosterone levels and CYP11B2 protein levels. This anti-aldosterone effect was associated with a reduction in the elevated systolic and diastolic BP. Conclusions and Implications:Tolvaptan inhibited AngII-stimulated aldosterone production via a V 2 receptor-independent pathway, which can counteract or even surpass its potential activating effect of diuresis-induced aldosterone secretion in certain aldosterone-mediated pathological conditions.

show abstract

Plasma corticotrophin response to desmopressin in patients with Cushing’s disease correlates with the expression of vasopressin receptor 2, but not with that of vasopressin receptor 1 or 3, in their pituitary tumours

Cited by 27 publications

References 47 publications

The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors

The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors

Multiple aberrant hormone receptors in Cushing's syndrome

Novel molecular mechanisms in the inhibition of adrenal aldosterone synthesis: Action of tolvaptan via vasopressin V₂ receptor‐independent pathway

Contact Info

Product

Resources

About

Plasma corticotrophin response to desmopressin in patients with Cushing’s disease correlates with the expression of vasopressin receptor 2, but not with that of vasopressin receptor 1 or 3, in their pituitary tumours

Cited by 27 publications

References 47 publications

The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors

The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors

Multiple aberrant hormone receptors in Cushing's syndrome

Novel molecular mechanisms in the inhibition of adrenal aldosterone synthesis: Action of tolvaptan via vasopressin V2 receptor‐independent pathway

Contact Info

Product

Resources

About

Novel molecular mechanisms in the inhibition of adrenal aldosterone synthesis: Action of tolvaptan via vasopressin V₂ receptor‐independent pathway